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BACKGROUND AND SCOPE
While we recognize and encourage the development ofalternative
research techniques which do not involve animals, we consider
that there are many questions in oncology research which can be
answered only by the study of tumours growing in vivo.
Animals with local or disseminated tumours are likely to
experience pain and/or distress, thus justifying special care and
attention from both licensees and others involved in their welfare.
Associated techniques including surgical preparation, irradiation,
and drug administration may increase the severity of an experi-
mental procedure. Recognizing this, the United Kingdom Co-
ordinating Committee on Cancer Research (UKCCCR) in 1988 set
up an ad hoc committee to develop guidelines for research
workers using animals in experimental neoplasia. The UKCCCR
(for membership see below*) is charged by the major bodies
involved in the funding of cancer research in the UK with the
co-ordination and development of areas in which they have a
common interest. The members of the ad hoc committee were
selected so as to represent a wide range ofspecialities which make
use of animal tumour models in cancer research together with
experts in animal husbandry and welfare and an observer from the
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Home Office Inspectorate. Feedback on the 1988 UKCCCR
guidelines has indicated that these were well received and have
been widely used in the UK, as well as having an influence over-
seas. It was explicitly stated in the 1988 guidelines that procedures
practised upon animals in cancer research, and in particular that
humane endpoints used, should be subject to a continuous process
of refinement. Indeed the 'Three Rs', that is reduction (in
numbers), refinement (of methods) and replacement (of animals
by othertechniques where appropriate) should constantly be borne
in mind by all users of experimental animals (Russell and Burch,
1959; Roush, 1966; Balls, 1994; Festing, 1994; Flecknell, 1994).
Both science and attitudes to animal work change. Accordingly, it
was envisaged in the 1988 guidelines that these would be modified
and updated as necessary. The present edition contains a number
ofchanges and will again be modified in the future should this be
necessary. To aid this process, feedback on the guidelines is
actively encouraged.
As before, particularemphasis withintheguidelines isfocused on
the prediction and recognition ofadverse effects and the implemen-
tation ofhumane end points. The majority of work in experimental
neoplasia utilizes small laboratory animals, particularly rodents.
Consequently we have drawn largely on available expertise with
*Member Organizations ofUKCCCR: Cancer Research Campaign, Imperial Cancer
Research Fund, Institute ofCancer Research, Leukaemia Research Fund, Ludwig
Institute for Cancer Research, Marie Curie Foundation, Medical Research Council,
Tenovus Cancer Fund.
Observers: Department ofHealth, Scottish Office Department ofHealth.
12 UKCCCR Guidelines
these species. However, the general principles are applicable to all
species of animal. It should be noted that these guidelines are not
intended to apply to the treatment of veterinary patients with
spontaneous tumours where different considerations apply. In
most instances induced models of neoplastic disease will be less
traumatic to the host animal than clinical disease.
The general welfare of laboratory animals and the performance
of regulated procedures upon them are both covered in the United
Kingdom by the Animals (Scientific Procedures) Act (1986) effec-
tive from 1 January 1987. Under this Act all scientific procedures
on living vertebrates which may have the effect of causing pain,
suffering, distress or lasting harm are controlled by the Home
Office and require specific authority through Personal and Project
Licences.
Guidance on the operation of the 1986 Act and Codes of
Practice for the Housing and Care of Animals have been produced
by the Home Office (see Bibliography). In addition, a number of
references which provide useful advice on general animal
husbandry and experimental techniques are listed in the
Bibliography.
The 1986 Act, together with the Home Office document listed
above and the 1987 Royal Society/UFAW Guidelines (see
Bibliography), provide a firm basis for experimental practice. We
would welcome the publication of further guidelines from expert
sources. We envisage that the present guidelines will be of general
value to workers carrying out experiments which involve the
growth of tumours in experimental animals, which arise sponta-
neously (including those in transgenic and gene 'knockout'
animals), are produced by transplantation (including routine
passage tumours, orthotopic tumours and hybridomas), or are
induced by carcinogenic agents. The guidelines may be especially
helpful in the completion of Project Licence applications, in
particular section 19b (v and vi) which requires that applicants list
the possible adverse effects and their likely incidence as well as
the proposed methods of controlling severity, e.g. the use of
analgesia, regional or local anaesthesia and sedation, and the
implementation of humane end points. The guidelines are not
mandatory. The term 'should' is used to encourage attainment of
desirable standards; the term 'must' is used only where legal
obligations apply.
The Recommendations are divided into two parts. The General
Recommendations are applicable to all regulated procedures. The
Specific Recommendations are more directly targeted to the
particular problems of experimental neoplasia. It is important to
emphasize that procedural guidelines, especially with respect to
implementation of humane end points, must be tailored to the
precise nature of each individual experimental neoplasia model.
To illustrate this, Appendix 1 gives some examples of criteria for
particular tumour systems. More detailed and specific information
regarding various procedures is given in Appendices 2-6.
RECOMMENDATIONS
General Recommendations
1. The following recommendations are based on the premise that
for each individual study those involved in the procedures
will weigh the likely adverse effects on the animals used
against the benefits likely to accrue from the work. Cancer is a
disease ofmajor unmet medical need and the potential benefits
ofcancer research are clear. Nevertheless, the feasibility of
using alternative methods not involving live animals should
always be considered. In vitro cell lines may be appropriate in
many instances as illustrated by the decision of the US National
Cancer Institute to replace the use of transplantable murine
tumours in primary anticancer drug screening with panels ofin
vitro human tumour cell lines (Boyd, 1986). Further examples
are the increasing use of in vitro methods (rather than ascites
tumours) for the production of monoclonal antibodies, and the
development of 'test cascades' for drug discovery in the phar-
maceutical industry (see Appendix 4). The use of animals for
study of the therapeutic effects of administered substances
without prior in vitro or ex vivo determination of likely biolog-
ical activity needs specific justification.
2. Where animals must be used, the degree of pain and distress
must be minimized by judicious use of anaesthetics and anal-
gesics, the refinement of experimental techniques, and the
early implementation of humane end points. Licensees must
know the severity limit for each regulated procedure (i.e. mild,
moderate, substantial or unclassified). The severity limit will
have been arrived at by agreement between the applicant and
the Home Office and takes into consideration details ofthe
procedure itself, the nature and incidence of any likely adverse
effects and any practical measures which will be used to mini-
mize severity. Standard conditions controlling the severity of
procedures attached to personal and project licences require
the Personal Licence to the notify the Project Licence holder
as soon as possible when it appears either that the severity
limit of any procedure or the constraints upon the adverse
effects described in the protocol sheets have been or are likely
to be exceeded. The Project Licence holder must notify the
Home Office Inspector ofthis at the earliest possible opportu-
nity. In addition, there is an inviolable termination condition in
all Personal Licences, which requires the Personal Licensee to
ensure the immediate humane death ofany animal in severe
pain or distress which cannot be alleviated.
3. Where certain procedures cause particular concern, these must
be addressed specifically in the Project Licence application. A
more detailedjustification for the procedure and precise defin-
ition of end points will be needed. The Home Office may
attach special conditions to such procedures including special
reports on the progress ofthe experiments.
4. The design of all experiments should meet the highest scien-
tific standards. It is important that pilot experiments should be
undertaken on small numbers ofanimals before new proce-
dures are carried out on a larger scale (see Appendix 2). All
available information from other sources should be collected
and carefully appraised before the design of (or need for)
appropriate pilot experiments is determined. The pilot experi-
ments should identify particular problems, define the time
scale ofcritical events, and help to refine the appropriate end
point. The use ofnew in vivo model tumour systems will
require a full initial investigation ofgrowth behaviour
including patterns oflocal invasion and/or metastatic spread in
a minimal number ofanimals. In all experiments the numbers
ofanimals used should be restricted to the minimum consistent
with the design and purpose ofthe experiment. Expert statis-
tical advice should be sought, especially by less experienced
investigators. In initial drug toxicity studies, 2 mice per group
will often be appropriate (Burtles etal, 1995).
5. All involved staff should be aware oftheir individual legal and
ethical responsibilities and a clear chain ofresponsibility and
British Journal ofCancer(1998) 77(1), 1-10 0 CancerResearch Campaign 1998UKCCCR Guidelines 3
consultation should be established. The decision-making
process should be designed so that, under all circumstances,
appropriate action is taken promptly to deal with any problems
which may arise, for example ifthe clinical condition of a
tumour-bearing animal deteriorates unexpectedly or ifthe indi-
vidual effects oftumour and therapeutic treatment are difficult
to distinguish (see section 3.5). Working protocols, including
details ofendpoints and signs ofadverse effects should be
made available to all those concerned with the care or use of
tumour-bearing animals.
6. All involved staff should receive appropriate training and
supervision for the required time period such as to be fully
competent in the procedures to be used. Systems for documen-
tation ofcompetence in different procedures should be in place
under the supervision ofthe Project Licence holder. Where
research workers are using unfamiliar procedures, information
and guidance should be obtained from experienced colleagues,
as well as from the scientific literature. For particularly skilled
procedures, the use ofexpert outside assistance is recom-
mended.
7. In the planning ofexperiments, due attention should be given
to whether resources are available such that it may reasonably
be expected that an answer to the scientific question will be
obtained. Such resources may, for example, include numbers
ofanimals ofsuitable strain, age and weight, appropriately
skilled manpower, and validated analytical methods.
SPECIFIC RECOMMENDATIONS
1. Assessment of severity
1.1 Before assessing the severity ofany procedure on the well-
being of an animal, it is essential that the licensees famil-
iarize themselves with the signs ofpain, discomfort and
distress in the species they are using, by consultation with
experienced colleagues, the named Animal Health and
Welfare Officer, the named Veterinary Surgeon and by refer-
ence to published guides (see Bibliography).
1.2 Particular attention should be paid to those body systems
most likely to be affected by the procedure. With solid
tumours this will include ulceration, distension ofcovering
tissues and cachexia. In the case ofascitic tumours, abdom-
inal distension, anaemia and cachexia will be important.
Lymphatic involvement from lymphoma and neurological
disturbance from interacerebral tumours are examples of
special complications arising in specific situations.
1.3 Certain deviations from normal well-being may be difficult
to observe, for example induction ofanaemia or the develop-
ment ofmetastases, and special investigations may be
required to detect them.
1.4 Appropriate control animals should always be included, so
that the individual effects ofthe tumour and ofany treatment
can be distinguished.
2. Biology of tumours
2.1 Due consideration should be given to the known biology of
the tumour. For spontaneous and transplanted tumours
important features will include growth rate, invasion, disten-
sion, ulceration, metastases, site, and production ofcachectic
factors. These features, which define the tumour profile,
should be established in pilot experiments. Methods of
tumour implantation or induction should be chosen so as to
minimize trauma to the host animal.
2.2 In the case oftumours induced by carcinogens, viruses or
genetic manipulation, factors such as method ofinduction
may affect the nature and location ofresulting tumours.
Animals at risk ofsuch tumours should be observed particu-
larly frequently for signs ofpossible tumour development or
associated disease.
2.3 Contamination oftumour cell lines with viruses and other
micro-organisms may compromise experimental results, as
well as causing an outbreak ofdisease among laboratory
animals. Screening ofcell lines for rodent viruses is strongly
recommended. For example, Sendai virus is often used to
induce cell fusion in vitro and is pathogenic to mice and rats.
A potential hazard exists for research workers from immune-
compromised animals receiving human tumour xenografts
which may be contaminated with human pathogens
including live viruses. In such cases, special facilities should
be considered for both tissue preparation and animal contain-
ment (e.g. flexible film isolators).
3. Humane considerations in experimental design
3.1 Considerable care should be given to thejudicious choice of
end point for tumour growth, bearing in mind the objectives
ofthe experiment and the underlying biology. This should
take into account predictable indications ofpain, distress or
significant deviation from normal behaviour. Unless speci-
fied otherwise on the Project Licence, animals should be
killed before:
i) predictable death occurs;
ii) they get into poor condition;
ii) the tumour mass becomes overlarge, likely to ulcerate or
unacceptably limits normal behaviour.
3.2 In the case oflocal solid tumours, the required information
on response to therapy may be obtained by tumour regrowth
delay, clonogenic assay following tumour excision or an
appropriate surrogate end point, rather than by tumour
weight at a given time. Difficulties may arise with this last
method because optimum shrinkage oftreated tumours may
not be achieved before control tumours become excessively
large and/or distressing to the host animal. Where such an
assay has to be used, the tumour burden should be regulated
as indicated in section 3.6.
3.3 The choice ofsite for transplantable or carcinogen-induced
solid tumours also requires considerable care, and particular
attention should be given to avoidance ofsites involving the
special senses or where the capacity for the tumour to grow
without causing pain or distress is limited. Subcutaneous or
intradermal growth on the back or in the flank are considered
to cause the least distress, while implantation oftumours in
the footpad, tail, brain and eye will require specialjustifica-
tion and is strongly discouraged. Distension ofmusculature
is generally painful and this should be considered with intra-
muscular implants. Extra attention must be paid ifmultiple
sites are used.
3.4 The intentional death end point should no longer be used.
This applies both to toxicity studies and to therapeutic
studies in animals bearing experimental tumours. Animals
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expected shortly to become moribund should be killed,
unless specified otherwise in the Project Licence.
3.5 Difficulties may occur where the effects ofanticancer agents
on tumour growth are being evaluated, and it is essential that
the individual toxic effects ofthe tumour and the treatment
are initially determined. The maximum tolerated dose ofthe
therapeutic agent (see Appendix 4b) should not be exceeded.
This dose may differ in control and tumour-bearing animals
and will require prior investigation.
3.6 No precise quantitative guide can be given as to the accept-
able upper limit oftumour burden, since the adverse effects
on the host will depend on the biology ofthe tumour, the site
and mode ofgrowth, and the nature ofassociated treatments.
However, tumour burden should not usually exceed 5% of
the host animal's normal body weight in the case ofanimals
being used for routine tumour passage, or 10% in animals
involved in therapeutic experiments. (This latter size, i.e.
10%, would typically represent a mean subcutaneous flank
tumour diameter of 17 mm in a 25 g mouse or 35 mm in a
250 g rat). Calibration curves relating tumour weight to
measured diameters should be established as part ofthe
initial characterization ofany new tumour system.
Consideration should be given to variation in measurement
between individual experimenters. Although the sizes given
above serve as a maximum guideline, it should be empha-
sized that problems may arise with much smaller tumour
burdens and the clinical condition ofthe individual animal
will always be the over-riding consideration.
3.7 In the case ofleukaemias, determination ofthe tumour
burden may be difficult. The development and use of appro-
priate biochemical and pathological laboratory methods to
determine the onset ofleukaemia prior to clinical signs is
strongly encouraged.
3.8 With all ascitic tumours care should be taken to ensure that
the volume ofascitic fluid does not become excessive,
causing gross abdominal distension, and that solid deposits
and cachexia are not allowed to become clinically signifi-
cant. Ascitic burden should not usually exceed 10% of
normal body weight in mice and rats. In view ofthe wide
availability of in vitro methodology, the use ofanimals for
monoclonal antibody production is increasingly difficult to
justify. Where authority exists for such use, it should be
noted that retired breeders are advantageous, since their
abdominal musculature more readily allows larger ascites
volumes to be tolerated without discomfort. Ascitic tumours
should be drained only after death.
3.9 Particular care should be taken with monitoring the
development oftumours in transgenic animals. Careful
clinical examination should be carried out to allow for the
detection ofboth predicted and unexpected sites oftumour
development. This should include measurement ofbody
weight changes, palpation and monitoring for deterioration
in clinical condition. Experience suggests that animals
should be examined at least twice weekly throughout their
life-span.
3.10 In tumour therapy experiments with adult rodents, it is
recommended that weight loss should not normally exceed
20% ofthe host body weight at the start ofthe experiment.
For younger animals, failure to maintain the weight gain
seen in untreated control animals should be considered as an
indication oftoxicity.
3.11 Care should be taken that general housing conditions
are appropriate to the known or anticipated condition
ofthe tumour-bearing animal, for example in terms of
appropriate bedding, cage structure and accessibility of
food and water.
3.12 Humane end points and other procedures should be
refined in the light ofexperience. (Also see section 5.2.)
4. EXAMINATION OF ANIMALS
4.1 The frequency with which animals must be inspected for
signs ofpain or distress and the extent ofeach examination
will be dictated by:
i) the known biology ofthe tumour and/or the effects ofthe
inducing agent;
ii) the effect ofany associated techniques;
ii) the changing clinical status ofthe animal.
4.2 Rapidly growing or invasive tumours will require more
frequent attention, and greater care will be required as the
tumour burden increases. As a minimum, every tumour-
bearing animal should be inspected daily and additional,
more detailed, examinations undertaken as appropriate. The
frequency ofthe latter should be increased during critical
periods where the potential for animal suffering may be
anticipated. The experimental design should ensure that
these do not occur when staff are absent. Particular attention
should be given to animals in poor health.
4.3 Appropriate assessment techniques will include: evaluation
ofoverall clinical condition, including appearance, posture,
body temperature, behaviour and physiological responses;
assessment offood and water intake; weighing to determine
changes in body weight (both positive and negative changes
compared to controls can be associated with increasing
tumour burden); caliper measurements to determine tumour
volume or mass; and inspection and palpation to locate the
sites oftumour growth, as well as to assess distension,
ulceration and compromised mobility.
4.4 Other special examination techniques will be more
valuable for specific sites, e.g. breathing rate for lung
deposits, neurological disturbance or irreversible weight loss
for brain neoplasms (Redgate etal, 1991) and blood cell
counts for leukaemias. Laparotomy or endoscopy may be
appropriate in some instances. Estimation ofcirculating
tumour marker substances may also be ofvalue.
Consideration should be given to the use of any novel
echniques which may be available. Autopsy ofanimals
may expose adverse effects undetected by external
examinations.
5. DOCUMENTATION AND PUBLICATION
5.1 It is essential that all animal experiments are carried out and
documented in accordance with Home Office regulations
and the principles ofsharing 'best practice'. Researchers are
strongly urged, for each tumour model in use in their labora-
tory, to document the expected behaviour ofthe tumour and
host animal under various experimental conditions,
including therapy. They should also document humane end
points to limit severity with regard to acute and delayed
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toxicity and maximal tumour burden, and indicate any
particular problems which may be encountered in the use of
each model. Such information should be incorporated into
working protocols and widely disseminated for the benefit of
others. The appropriate response to problems which have
been or may be encountered should be described and the
chain ofconsultation and responsibility clearly defined.
Particular care should be taken that all procedures are under-
stood byjunior and occasional staff. Consideration should be
given to the inclusion ofa numerical scoring system to facil-
itate decision-making, e.g. when to contact senior staffor to
kill an animal. The guidelines for specific tumour models
should be readily available to, and agreed between, all
research and animal husbandry staffinvolved with that
model. Instructions for the appropriate use ofanaesthesia
and/or analgesia should be included. Researchers are again
urged to share this information with other groups using the
same system, for example when providing a tumour cell line
to another laboratory.
5.2 Researchers are encouraged to publish improvements in
humane end points in appropriatejournals, so as to ensure
wide dissemination ofthe information.
5.3 Encouragement is given to incorporate animal welfare state-
ments into experimental protocols, and in addition to report
compliance with these and other appropriate guidelines
(including any local ones) when publishing results. Certain
journals require or encourage this (e.g. British Journal of
Radiology, British Journal ofCancer, Cancer Chemotherapy
and Pharmacology, Cancer Research, and the Journal ofthe
National Cancer Institute) and we would urge otherjournals
to adopt such a policy.
SUMMARY AND CONCLUDING REMARKS
Researchers have a legal and ethical responsibility for the welfare of
experimental animals in their care and due consideration should
always be given to the 'three R's' (reduction, refinement, replace-
ment). They must decide whether, for each individual experiment,
the use of animals isjustified to answer a particular question, and, if
so, minimize the pain and distress involved. Studies in experimental
neoplasia present particular problems. Workers should possess
adequate knowledge of the animals and tumour systems to be used.
Where unfamiliar procedures are to be employed, information and
guidance should be obtained through consultation with experienced
colleagues and from the scientific literature. Workers should receive
appropriate training and supervision. Pilot experiments should be
carried out with small numbers of animals, and numbers should
always be restricted to the minimum consistent with the design and
purpose ofthe experiment. Tumour end points should be chosen and
refined so as to minimize the adverse effects on the host animal.
Death as an end point should no longer be used. The use ofanimals
for monoclonal antibody production is increasingly difficult to
justify due to the availability ofalternative methods. Ascites tumours
should only be drained after the death ofthe animal. The use of new
technologies will present new opportunities and problems which will
need to be taken into account. All staff should understand their
individual responsibilities, and a clear chain of responsibility and
communication should be established so that prompt action can be
taken to deal with any problems that arise. Finally, researchers are
encouraged to refine end points in experimental neoplasia and to
disseminate best practice by publishing such improvements, to
incorporate welfare statements in experimental protocols, and to
report compliance with appropriate guidelines in publications.
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APPENDICES
APPENDIX 1 - Model Tumour Systems
The following examples oftumour systems are given forillustration.
a) A transplantable mouse tumour with a choice ofthera-
peutic endpoints (RIF-1 fibrosarcoma). This is a trans-
plantable sarcoma ofC3H/Km mice which is widely used in
radiation and chemotherapy studies (Twentyman et al,
1980). It can be maintained in cell culture and is grown in
vivo as a solid tumour by implantation intradermally in the
skin ofthe flank or intramuscularly in the hind leg. The end
points used to determine therapeutic effects on the solid
tumour are clonogenic survival, regrowth delay and tumour
cure. It is common practice to terminate regrowth delay
experiments with leg tumours when the maximum limb
diameter reaches approximately 15 mm or with subcuta-
neous tumours in the flank at a mean diameter of 17 mm. At
this point the tumour mass is about 2.5 g or about 10% ofthe
body weight and the host animals are in otherwise normal
condition. Growth delay is determined from the time to
reach four times the treatment size. Metastases occur late
and rarely.
b) Rodent tumour metastasis models. Metastases may be
seeded either 'artificially' by intravenous injection of tumour
cells, or spontaneously after growth of a solid deposit which
can be removed surgically when appropriate. Such models
include the B16 and other melanomas and UV-induced
fibrosarcomas in mice (Kripke et al, 1978). It may not be
necessary to wait until mice develop symptoms of
impending morbidity, and the required information may be
obtained after humane killing at an earlier stage (see Kripke
et al, cited above). Special attention should be directed to
detecting signs associated with clinically significant disease
in sites particularly susceptible to metastasis, e.g. dyspnoea
due to lung deposits.
c) A mouse leukaemia (L1210). This is normally grown as an
ascites tumour and used for the evaluation ofanticancer
agents (Geran et al, 1972). The difficulties associated with
this model are also shared by other ascites tumour models
for which the survival end point has been widely used in the
past, but should no longer be used. Cells (routinely 105_106)
are injected into the peritoneal cavity ofC57BL xDBA/2F,
(DB2F,) mice. A direct relationship normally exists between
the number ofviable L1210 cells injected, or remaining after
drug treatment, and the subsequent survival ofthe animal.
Implantation of 105 L1210 cells, with a doubling time of
approximately 12 hours in exponential growth, has been
shown to produce life-threatening symptoms by the eighth
day after implantation. These symptoms are manifested as a
marked abdominal distension produced by peritoneal ascitic
fluid, dyspnoea, a hunched posture and poor coat quality,
particularly a ruffling ofthe fur, and mild catatonia. As
animals approach this phase of tumour growth, twice daily
inspection oftumour-bearing animals is necessary to assess
morbidity andjudge the appropriate time for the animal to
be killed. The therapeutic substance under investigation is
normally administered 24 hours after the implantation ofthe
tumour, and may be given at subsequent times. However, the
protocol may be modified so as to avoid possible temporal
overlap ofthe toxicity ofthe substance and the symptoms of
morbidity induced by the tumour.
d) A mouse tumour which produces cachexia (MAC 16
mouse colonic adenocarcinoma). This is a transplantable
tumour ofNMRl mice which is normally grown subcuta-
neously in the flank (Bibby et al, 1987). It is ofparticular
interest because it causes progressive cachexia and loss of
body weight, beginning at a tumour weight ofabout 100 mg
in a 30 g mouse and increasing over the subsequent 7-14
days. The host mice continue to eat normally over this
period. The main difficulty in working with the MAC 16
tumour is the heterogeneity ofcachectic response between
animals with similar tumour burdens. Because ofthis, indi-
vidual animals are weighed at the time oftransplantation and
then daily thereafter. Mice are killed when the weight loss
reaches a maximum of20%. This careful monitoring proce-
dure prevents the occurrence ofdeath due to cachexia.
e) Chemically induced skin tumours in mice. A common
method for assessment ofthe carcinogenicity ofa chemical
is the induction ofskin tumours in mice. Chemicals can be
tested for their capacity to initiate or promote the develop-
ment ofbenign lesions, or to influence rates ofprogression
to malignancy. Particular care should be taken in choosing
the strains of mice used for such studies. Some strains, such
as C56B1/6 or BalB/C, are relatively resistant to two-stage
skin carcinogenesis and therefore statistically significant
results may not be obtained. Certain strains are also very
sensitive to treatment with tumour promoters such as TPA,
which can become evident as skin ulceration after the first
1-3 weeks oftreatment. In such cases, the treatment should
be stopped (ifreaction is severe), or continued at reduced
levels. Animals can develop multiple benign papillomas
within 6-8 weeks, which increase in number and/or size up
to about 20 weeks. It is not advisable to continue promoter
treatment beyond 20 weeks, since this has no effect on rates
ofmalignant progression. The overall health status ofmice
bearing papillomas is generally acceptable, except when
their number or size becomes excessive, at which point the
animals should be humanely killed. Particular care should be
paid to animals bearing papillomas which show signs of
progression to malignancy. Carcinomas can increase rapidly
in size and can metastasize to other body sites. This should
be monitored as described in Section 4.3.
f) Spontaneous mammary adenocarcinomas in T138 mice.
Breast cancer is a complex disease. To facilitate biological
and therapeutic studies ofthis cancer, relevant experimental
models are needed which mimic closely the human disease.
Most current studies using animal systems involve the trans-
plantation ofmurine or human cancer tissue in mice.
Although these experimental systems facilitate much under-
standing ofthe disease, they do not accurately reflect many
ofthe disease associated parameters, e.g. age related inci-
dence, progression ofthe disease from a spontaneously
transformed single cell in vivo. Female mice ofthe T138
mouse strain develop spontaneous mammary adenocarci-
nomas with an incidence ofgreater than 90% (Wood et al,
1992; Nordsmark et al, 1996). The tumours only arise in
mice older than 8 months ofage and the incidence vs. age
(as offraction oflife span) closely mirrors that seen in
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humans. Initial crossbreeding with CBA mice (both male
and female) suggests that the tumour incidence is not
induced by MMTV passed in the mothers' milk. The T138
parent carries a reciprocal chromosome 9-17 translocation.
Whether the incidence ofthe tumour is associated with this
translocation is not yet known.
g) Chemically (DMBA) induced rat mammary tumours.
(Huggins et al, 1959). Setting a humane end point with this
tumour is difficult. There is heterogeneity in both the number
oftumours which develop and in their relative growth rates,
"
so that individual animals may have widely differing tumour
burdens. Close daily monitoring is essential and an overall
judgement must be made, based on the aggregate tumour
mass, the size and condition oflarger tumours, and the
general health ofthe animal. While animals may tolerate an
aggregate tumour burden of> 10% ofbody weight ifthere
are many small tumours, a single large tumour can lead to
rapid deterioration necessitating humane killing ofthe
animal.
h) Chemically-induced colonic tumours in rats. Tumours of
certain internal organs are difficult to detect by external
examination. As an example ofthe use ofspecial diagnostic
techniques, colonic tumours in rats can be identified by
endoscopic examination (Merz etal, 1981; Hermanek and
Giedl, 1984).
i) Genetic manipulation.
(1) Neoplasia in transgenic animals Problems may be
encountered when oncogenes are inserted or activated, or
indeed other genetic alterations are introduced into recip-
ient transgenic animals. In particular it may be difficult to
predict the consequences ofsuch genetic changes, which
may occur other than in the particular organ ofinterest. An
example ofthis occurred in transgenic mice carrying a
hybrid gene comprising the murine oc A-crystallin
promoter fused to the coding sequence ofthe oncogene
SV40 T antigen. Not only did the expected lens tumours
develop, but in addition several animals developed non-
lenticular tumours at various sites throughout the body
(Mahon etal, 1987). Thus special care must be taken to
ensure that such associated sequelae are identified and
appropriate measures taken.
(2) p53 knockout mouse (Donehower etal, 1992) Mutations
in the p53 gene are the mostfrequently observed genetic
lesions in human cancers. To investigate the role ofthe p53
gene in mammalian development andtumorigenesis a null
mutation was introduced into the gene by homologous
recombination in mouse embryonic stem cells. The mice
homozygous for the null allele appear normal but are prone
to the development ofa variety ofneoplasms. Approximately
75% ofhomozygotes develop tumours by 6 months ofage
with the mean time to the appearance oftumours being 20
weeks. The most frequently observed tumours are malignant
lymphomas and sarcomas. Heterozygous p53 mice have a
low spontaneous rate oftumorigenesis, about 2% at 9 months
ofage. This is a powerful model for studying the loss ofp53
tumour suppressor function, testing chemopreventative and
chemotherapeutic agents andearly stage carcinogenicity
testing, but detection ofearly lesions requires very careful
monitoring.
(3) APCMIn Mouse Model (Moser etal, 1990) Min
(Multiple Intestinal Neoplasia) is an ethylnitrosurea (ENU)
induced mutation in the murine APC (adenomatous poly-
posis coli) gene. This is similar to the germline mutations
in the APC gene in humans with the inherited colon cancer
syndrome, familial adenomatous polyposis, which is the
most frequently mutated gene in sporadic colon tumours in
humans. MinIMin homozygous mice are not viable
whereas Min/+ raised on a high fat diet develop adenomas
throughout the intestinal tract. The majority oftumours are
located in the small intestine causing related anaemia or
bowel obstruction within 120 days. Again, therefore,
careful and frequent monitoring is mandatory. This model
has been used for the evaluation ofchemopreventative
agents (e.g. sulindac) and to study colon tumorigenesis.
APPENDIX 2 - Tumour profiling and transplantation
a) Tumour profiling
Prior to embarking on experiments with new transplantable
tumour models, these should be properly characterized. This
requirement extends to both tumours that have arisen within
the home laboratory and tumours imported from other labo-
ratories. For the latter category there may be published data
on tumour growth characteristics and a thorough literature
review should be conducted to establish the known proper-
ties ofthe tumour. Special attention should be paid to the
selection ofthe host animal strain to be used since small
strain differences can have unpredictable effects on tumour
behaviour and host tolerance. This may be particularly true
of ascitic or metastatic tumour models.
In most cases it is advisable to perform pilot tumour
growth studies using small groups ofanimals (5-10) in order
to establish that the pattern oflocal and metastatic growth is
both humane and reproducible. For example:
(i) primary tumours implanted in the flank may undergo
early necrosis dependent on the implantation method (e.g.
injection ofcells or surgical implantation oftissue frag-
ments), (ii) intramuscular tumours in the leg can affect
mobility, (iii) with ascitic tumours it is important to estab-
lish clinical criteria that ensure animals will always be
killed before the humanely acceptable maximum tumour
burden is exceeded, (iv) with metastatic models, the pilot
experiments should include a full definition ofthe extent
and time course ofthe spread ofthe tumour to internal
organs. Where possible, methods should be developed to
assess metastatic spread so that animals can be killed
before tumour growth in internal organs leads to an unac-
ceptably poor condition.
b) Tumour transplantation
With tumour cell suspensions, permitted administration
volumes should be as defined for the injection volumes of
vehicles for drug administration (see below, Appendix 4e).
Solid tumour fragments should be as small as practical, so as
to be transplantable via a small diameter trocar without the
use ofanaesthetics. Use of larger fragments (up to 3 mm
linear dimension) can be transplanted via trocar with anaes-
thesia or surgical incision may be necessary. A technique
similar to that used for small fragments is recommended for
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the implantation of 'hollow fibres' (Hollingshead et al,
1995) for which the original NCI protocol of surgical
incision with anaesthesia is not deemed necessary.
APPENDIX 3 - Humane endpoints and limiting clinical
signs
Experimental protocols and severity limits in project licences
should specify early experimental or humane end points requiring
appropriate intervention. Criteria for such endpoints should be
determined before the study commences. The following clinical
signs may be useful:
1) Persistent anorexia or dehydration.
2) Consistent or rapid body weight loss of20% maintained for
72 h.
3) Unable to maintain an upright position or to move.
4) Muscle atrophy or emaciation.
5) Moribund, lethargic or failure to respond to gentle stimuli.
6) Hypothermia.
7) Unconscious or comatose.
8) Bloodstained or mucopurulent discharge from any orifice.
9) Laboured respiration - particularly ifaccompanied by nasal
discharge and/or cyanosis.
10) Enlarged lymph nodes or spleen.
11) Anaemia
12) Ulcerated tumours or large tumours that interfere with
normal movement.
13) Significant abdominal distension or where the ascites burden
exceeds 10% ofthe baseline bodyweight.
14) Incontinence or prolonged diarrhoea.
Where any one of these signs is present in a single animal then
the animal should be killed immediately and any remaining
animals observed closely for changes in their condition.
APPENDIX 4- Experimental Chemotherapy
a) Drug development 'test cascades'
The recent increase in our understanding ofthe genes
responsible for cancer causation has opened up a range of
opportunities to define novel, technically feasible, molecular
targets for the discovery ofinnovative anticancer agents that
are more effective and/or selective than existing drugs (Kerr
and Workman, 1994). As a result, much greater emphasis is
now placed on demonstrating activity at the desired
molecular locus than on 'random screening' for cytotoxicity.
Contemporary small molecule drug discovery programmes
in pharmaceutical industry commonly employ the type of
sequential test cascade depicted in the Figure 1. This
involves a sequence ofhierachical tests, beginning with in
vitro biochemical and cellular assays and progressing
through tests for bioavailability to assays for activity in
animals, e.g. in a surrogate in vivo model or a human tumour
xenograft in immunosuppressed mice. By the use ofiterative
cycles ofstructural modification and biological evaluation
with emphasis on evidence ofmechanism-based mode
ofaction, properties such as potency, selectivity, pharmaco-
kinetics, pharmacodynamics and therapeutic index can be
optimized. The initial lead compound is often identified by
high throughput screening (HTS) in vitro, usually with
Assay
Biochemical Screen
Usually high throughput test with
recombinant reagents)
Number of
Compounds tested
Typically 200,000-500,000
compounds
terati *- Rational design
lead 4- Structural biology
CLls Asssdevelopment *- Combinational chemistry
Target CellsAssays
(To measure cell, activity,
selectivity, mode of action) 1000-5000
Pharmacokinetic endpoint
(eg blood level as a
measure of drug exposure)
and/or
Surrogate endpoint
(eg normal tissue or animal
tumour response as a measure
of biologal effect)
Disease model
(eg human tumour xenograft)
Specific organ toxicity
(Typically 0.5-1% hit rate trom
high throughput screen)
(100%)
50-1000
(5-20%)
20-250
(2-5%)
10-50
(1%)
Figure 1 A typical contemporary drug discovery test cascade. Note that the
figures in parenthesis are percentages of the total number of compounds
which were tested in the target cells assays. Thus in the example shown, the
number of compounds tested in the disease model is 2-5% of the number
tested in cells. With respect to the total number of compounds tested in the
biochemical screen, the proportion is very much lower. It should be noted that
the figures shown represent a typical range for illustration. The number and
proportions will vary with different projects. However, the key message is that
the use of an informative test cascade will very considerably reduce the
proportions of compounds that enter in vivo testing.
recombinant reagents, ofa very large number of structures
present in a diverse compound library. The HTS approach is
often complemented by rational design and use of structural
biology or molecular modelling. Construction ofthe test
cascade should be tailored to the individual programme. It
should be noted that some tests may be omitted as the
programme matures, in particular within a closely related
chemical series. The use ofthe test cascade means that only
a relatively small proportion ofthose compounds tested in
vitro progress to evaluation in animals, and the likelihood of
those that are tested in vivo having the desired properties is
thereby enhanced.
b) Maximum tolerated dose (MTD)
To minimize the number ofanimals at risk ofexperiencing
toxicity in efficacy studies, pilot studies utilizing 2 non-
tumour-bearing animals per dose level, and a dose escala-
tion/de-escalation design, are recommended. Ideally,
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increasing dose levels should be initiated at 2-3 day inter-
vals, or longer ifdelayed side-effects are anticipated, in
order to minimize the numbers ofanimals exposed to poten-
tially lethal doses. Ifdose escalation with a time interval
between dose levels is impractical then no more than 3 dose
levels should be tested together, so that no more than 6
animals could potentially experience life-threatening toxicity
in the study. When greater precision in MTD determination
is required (e.g. for therapeutic ratio calculations on potential
drug candidates) 5 to 10 animals may be required. However,
the study should be limited to no more than 3 dose levels in
the dose range where life-threatening toxicities are predicted
from pilot studies.
When initiating studies in tumour-bearing animals, it is
important to recognize that the presence ofthe tumour may
reduce the tolerance ofthe host to the toxic effects of a
therapy. Consideration should be given to performing pilot
experiments to confirm that the MTD established in non-
tumour-bearing animals is also tolerated in animals with
tumours.
c) Pharmacokinetics (PK) and pharmacodynamics (PD)
PK studies can be useful as a prelude to efficacy studies to
determine whether or not potentially active drug concentra-
tions, derived by extrapolation from in vitro data, can be
achieved in vivo at tolerated doses. In addition, PK and PD
studies in tumour-bearing animals are an important compo-
nent ofcontemporary drug discovery and development
programmes (see Appendix 4a). In vivo PK studies should
not be initiated until adequately validated methods have been
developed for the analysis ofthe test substance in the
required tissue or biological fluid.
PK and PD studies should usually be performed at thera-
peutically relevant doses and should not therefore be carried
out without some knowledge ofthe MTD, such as a 2 animal
pilot study. Prior to embarking on full scale studies to
comprehensively describe PK and PD parameters, it is
recommended that a small pilot study with 3 animals per
group and up to 5 time points covering the critical range is
performed. Ifthe drug concentrations or PD effects observed
are far from those required then full studies may not be
warranted. Wherever possible, blood and tissue samples
should be collected at post-mortem, after killing by an
approved technique.
d) Specific organ toxicity
In these studies it is often necessary to give doses that will
affect animal condition, although these should not be so high
as to lead to death. It is therefore essential that the MTD has
been defined, so that appropriate doses can be selected. Also,
animals should be killed as soon as an adequate biochemical,
or other measure or index ofspecific organ toxicity, has been
obtained. In all cases, animals must be killed before the
onset of substantial toxicity. The number ofanimals per dose
group should be selected by taking account ofthe type of
endpoint to be used, and the statistical precision required. In
these studies very careful monitoring ofeach animal,
including frequent measurement ofbody weight, food and
water consumption, urine output, and clinical signs, is essen-
tial to obtain maximum value from terminal tissues analyses.
e) Administration, volume & vehicle
As a general principle, injection volume should be kept to the
minimum that is practical for accuracy and reproducibility.
Vehicles should be as physiologically compatible as possible.
It should also be borne in mind that laboratory formulation
problems could extend to the clinic, e.g. DMSO is not readily
acceptable for mice or man. The organic solvent portion, e.g.
DMSO, DMA or ethanol, ofa formulation vehicle for any
route ofadministration should not exceed 10% and the
concentration ofdetergents or emulsifiers should not exceed
20%. The use ofoil suspension should be discouraged. For
mice, a maximum injection volume of0.1 ml per 10 g body
weight should not be exceeded. While it has been fairly
common practise to extend this proportion to larger species,
e.g. rats, this can no longer bejustified on the grounds of
simplicity, and with animals weighing more than 1000 g
every effort should be made to use an injection volume of
0.01 ml per 10 g body weight.
APPENDIX 5 - Gene Therapy
Gene therapy provides a promising alternative approach to therapy
for cancer, as well as arange ofother human genetic diseases. The
design of the therapy depends on the nature of the disease.
Treatment ofdiseases caused by single gene defects, such as cystic
fibrosis, may involve simply replacing the defective gene with a
functional copy within the diseased airway epithelia cells. For
more complex diseases, such as cancer, which involve defects in
multiple genes, other approaches include delivery of genes which
are specifically toxic to tumour cells or which induce more active
tumour cell killing by the immune effector cells. The genes in all
of these cases can be delivered as naked DNA, encapsulated in
liposomes, or in retroviral or adenoviral vectors. In some cases,
particularly in the case of adenoviral vectors for cystic fibrosis,
some inflammation of the infected tissues has been observed, but
the design of the new vector systems may circumvent this
problem. The main difficulty with gene therapy in deliver of the
therapeutic gene to a sufficient number of target cells. For
diseases like cystic fibrosis, this problem can be at least partially
alleviated by the ability of cells to communicate with each other.
In this way, a single cell which takes up the therapeutic gene can
pass on the beneficial effects to its neighbouring cells. A similar
"bystander effect" has been shown in model systems to be useful
for the transfer of toxic metabolites between cancer cells after
delivery of genes encoding enzyme prodrug activation systems.
Another promising approach uses viral vectors which are capable
of self-replication, ensuring more efficient delivery to a higher
proportion of the target cells. In this case, specific safety features
have to be built into these replication-competent viruses to ensure
replication only within tumour cells. Clinical trials of many of
these therapies are presently being carried out in hospitals world-
wide. There is little information on long-term sequelae as most
experiments are over short periods of time. There is a formal
possibility of recombination, integration or transformation events
with retroviral vectors but no evidence, so far, that this occurs.
APPENDIX 6- Ethical Review
Extract (with permission) from a Home Office guidance
document on: Local Ethical Review Processes
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'A local ethical review process could provide a mechanism to help
certificate holders in meeting their responsibilities and could be
the means of encouraging wider local involvement in addressing
issues surrounding animal use. At the practical level, such consid-
eration might involve asking whether the particular animal use
proposed was appropriate and, ifso, how the least animal suffering
might be caused and welfare maximized.
The Home Secretary does not intend that any process over and
above what is already required by the 1986 Act should be made
mandatory. He invites you to consider, however, whether or not
your own establishment would benefit from one or other of the
local ethical review processes described above. The aim would be
to maintain the awareness ofall involved in laboratory animal care
and use oftheir responsibilities towards their animal charges. Any
of the ways described above would encourage this. Some of the
processes will be more suitable for some institutions than others.'
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